Long term results of vaccination against viral hepatitis B using recombinant vaccine Engerix B
Juszczyk, J.; Barałkiewicz, G.
Przeglad Epidemiologiczny 46(4): 271-279
1992
ISSN/ISBN: 0033-2100 PMID: 1305775 Document Number: 398054
Among nineteen persons vaccinated against hepatitis B (recombinant Engerix B vaccine) fifteen (80 per cent) have developed anti-HBs (investigated 30 days after the third doses) on the protective level (10 U/l). After three and a half year three of them lost antibodies, and four had anti-HBs at level below 100 U/l. All of them received a booster doses, which resulted in a very high anti-HBs level one month later. Four persons without anti-HBs after the basic vaccination received in turn two booster doses: at the 3rd and 46th month. Only one person of them have remained a non-responder. We suggest to control a level of anti-HBs one month after basic vaccination for individual determination of the term of booster dose.